BIOMARIN PHARMACEUTICAL INCBMRNEarnings & Financial Report
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
BMRN Q1 FY2026 Key Financial Metrics
Revenue
$766.2M
Gross Profit
$571.2M
Operating Profit
$129.6M
Net Profit
$106.0M
Gross Margin
74.6%
Operating Margin
16.9%
Net Margin
13.8%
YoY Growth
3.0%
EPS
$0.54
BIOMARIN PHARMACEUTICAL INC Q1 FY2026 Financial Summary
BIOMARIN PHARMACEUTICAL INC reported revenue of $766.2M (up 3.0% YoY) for Q1 FY2026, with a net profit of $106.0M (13.8% margin). Cost of goods sold was $195.0M, operating expenses totaled $441.6M.
Key Financial Metrics
| Total Revenue | $766.2M |
|---|---|
| Net Profit | $106.0M |
| Gross Margin | 74.6% |
| Operating Margin | 16.9% |
| Report Period | Q1 FY2026 |
BIOMARIN PHARMACEUTICAL INC Annual Revenue by Year
BIOMARIN PHARMACEUTICAL INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.2B).
BIOMARIN PHARMACEUTICAL INC Quarterly Revenue & Net Profit History
BIOMARIN PHARMACEUTICAL INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $766.2M | +3.0% | $106.0M | 13.8% |
| Q4 FY2025 | $874.6M | +17.0% | $-46.6M | -5.3% |
| Q3 FY2025 | $776.1M | +4.1% | $-30.7M | -4.0% |
| Q2 FY2025 | $825.4M | +15.9% | $240.5M | 29.1% |
| Q1 FY2025 | $745.1M | +14.8% | $185.7M | 24.9% |
| Q4 FY2024 | $747.3M | +15.6% | $124.9M | 16.7% |
| Q3 FY2024 | $745.7M | +28.3% | $106.1M | 14.2% |
| Q2 FY2024 | $712.0M | +19.6% | $107.2M | 15.1% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $712.0M | $745.7M | $747.3M | $745.1M | $825.4M | $776.1M | $874.6M | $766.2M |
| YoY Growth | 19.6% | 28.3% | 15.6% | 14.8% | 15.9% | 4.1% | 17.0% | 3.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.07B | $6.85B | $6.99B | $7.15B | $7.46B | $7.61B | $7.59B | $8.59B |
| Liabilities | $1.78B | $1.44B | $1.33B | $1.35B | $1.43B | $1.56B | $1.51B | $2.38B |
| Equity | $5.29B | $5.41B | $5.66B | $5.79B | $6.03B | $6.06B | $6.09B | $6.21B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $118.8M | $221.5M | $185.6M | $174.4M | $185.3M | $368.7M | $99.6M | $220.7M |